Full Press Release Details
Curis, Inc. (NASDAQ: CRIS) Corporate Overview June 20, 2005
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including statements about Curis drug discovery and development programs. Such statements may contain the words believes , expects , anticipates , plans , seeks ,
estimates or similar expressions. These forward looking statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other factors that may cause Curis actual results to be materially
different from those indicated by such forward-looking statements. Actual results can be affected by a number of important factors including, among other things: adverse results in Curis and its strategic partners product development
programs; and difficulties or delays in completing clinical trials and obtaining or maintaining required regulatory approvals for such development programs; Curis ability to obtain or maintain the patent and other proprietary intellectual
property protection necessary for the development and commercialization of products based on its technologies; changes in or Curis inability to execute its realigned business strategy; the risk that Curis does not obtain the additional funding
required to conduct research and development of its product candidates and execute on its business plan, including the capital required to fund its co-development option with Genentech; unplanned cash requirements and expenditures; risks relating to
Curis ability to enter into and maintain important strategic partnerships, including its ability to maintain its current collaboration agreements with Ortho Biotech, Genentech, and Wyeth; the risk that competitors will discover and develop
signaling pathway-based therapeutics or alternative competing therapeutics faster and more successfully than Curis and its collaborators are able to; and other risk factors identified in Curis most recent Annual Report on Form 10-K, Quarterly
Report on 10-Q and any subsequent reports filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent the Company s views only as of today and should not be relied upon as representing its views as
of any subsequent date. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this presentation whether as a result of new information, future events or otherwise.
Collaborations and Product Candidates
Collaboration strategy improves probability of success
Portfolio approach results in product diversity (i.e., technology platform, compound type, and target indication)
Payments from collaborators lessen future dependence on capital markets
Cash milestones under top four deals total $650 million
Diverse collaboration structures allow for calculated risk assumption and retained technology rights
Curis is co-developing a skin cancer product with Genentech
Research capabilities ensures pipeline of new drug development candidates
Collaboration strategy improves probability of success
Portfolio approach results in product diversity (i.e., technology platform, compound type, and target indication)
Payments from collaborators lessen future dependence on capital markets
Cash milestones under top four deals total $650 million
Diverse collaboration structures allow for calculated risk assumption
Curis is co-developing a skin cancer product with Genentech
Research capabilities ensures pipeline of new drug development candidates
Collaborator Technology Compound Primary Indication
Genentech CURIS Hh pathway Small molecule Basal cell carcinoma
antagonist (topical formulation)
Genentech Hh pathway Sm. mol. Antag. Other solid tumors
and antibodies (systemic formulation)
Wyeth Hh pathway Small molecule Stroke and other
agonist neurological disorders
ORTHO BIOTECH BMP pathway Protein agonist Chronic kidney disease
and related disorders
Genentech Undisclosed Small molecule Not disclosed
Genentech Undisclosed Small molecule Not disclosed
Collaboration strategy improves probability of success
Portfolio approach results in product
diversity (i.e., technology platform, compound type, and target indication)
Payments from collaborators lessen future
dependence on capital markets
Cash milestones under top four deals total $650 million
Diverse collaboration structures allow for calculated risk assumption
Curis is co-developing a skin cancer product with Genentech
Research capabilities ensures pipeline of new drug development candidates
Curis Program Technology Compound Primary Indication
CURIS Hh pathway Small molecule Hair growth
agonist (topical delivery)
CURIS Hh pathway Nucleic Acid Cardiovascular
CURIS Discovery Small Spinal Muscular
Screening molecule Atrophy1
CURIS Discovery Small Not disclosed
1 Supported by a $5.4 million grant from the Spinal Muscular Atrophy Foundation. Any compounds derived from SMA program are owned by Curis.
Collaborations and Product Candidates
Patents/Financials/Summary
Regulated by Signaling Pathways to Build the Body s Tissues and Organ Systems
Stem Progenitor Specialized Cells Cells
Cells can Lead to Proliferation of Cancer Cells
Unregulated Signaling Pathways
can Block Cancer Growth
Signaling Pathway Antagonist
Unregulated Signaling Pathways
Collaborations and Product Candidates
Patents/Financials/Summary
Basal Cell Carcinoma and other Solid Tumor Cancers
Collaboration with Genentech
Antagonist Collaboration
Established: June 2003
Deal structure: $8.5 million up-front payment, development milestones, product royalties, minimum two years R&D support, BCC
co-development option in U.S.
Primary indications: Topical treatment for basal cell carcinoma (co-development program with
Curis) and systemic treatment of other solid tumors
Antagonist Collaboration: Recent Progress
Genentech doubles the number of Curis personnel on Hedgehog antagonist program
Curis personnel are supporting systemic solid tumor program
Genentech extends research funding under the Hedgehog antagonist program from June 2005 to at least December 2005
Curis exercises co-development option with Genentech for an equal share of U.S. costs and profits for a basal cell carcinoma product
IND for basal cell carcinoma product candidate is filed and approved by FDA
First patients treated in Phase I clinical trial
Antagonists can Eliminate Basal Cell Carcinoma
Basal Cell Carcinoma Model
Untreated skin cancer model
treated w/ topical small molecule Hh antagonist
from Williams et al, 2003
Carcinoma (BCC) Genentech Curis Co-Development
Co-development: Profit sharing structure commensurate with cost-sharing
contributions; equal participation option exercised February 2005
BCC Phase I initiation: April 2005
Disease incidence: 800,000 to 1 million cases annually in the U.S.*
Marketing advantage: Non-surgical treatment for skin cancer that occurs primarily on face and hands
* American Cancer Society; Skin Cancer Foundation
Antagonist Pilot Human Clinical Study
Study goal: To assess the potential of a Hedgehog (Hh) pathway antagonist as a
treatment for basal cell carcinoma (BCC)
Hh antagonist: Cyclopamine
Study design: Four patients with established BCCs, who were scheduled for excision surgery, treated topically with cream containing
cyclopamine or placebo (4X/d, 3-6 days)
Literature citation: Eur. J. Dermatol. 2004 14(2):96-102 from Ta and Avci, 2004